Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS
pharmaceutical investing Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS (eflapegrastim) Data
LAURION Intersects High-Grade Gold, Silver and Zinc at Ishkoday A-Zone/McLeod/CRK Zone, Confirming Structural Continuity Along Mineralized Corridor